Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.61 |
| ▸ | HTT | P42858 | 4/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 5/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | LDHA | P00338 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | ABL1 | P00519 | 1/20 | 0.57 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29602721 | 1.00 | LMNA (0.61) | LMNAHTTNPC1EPHX2GAA | |
| SCHEMBL4163008 | 0.90 | MAPK1 (0.63) | LMNAHTTNPC1EPHX2GAA | |
| Trifluoroacetic Acid SCHEMBL6424557 | 0.89 | LDHA (0.53) | LMNAHTTNPC1EPHX2GAA | |
| SCHEMBL4638474 | 0.88 | MAPK1 (0.56) | LMNAHTTNPC1EPHX2GAA | |
| SCHEMBL10701749 | 0.87 | PTGER3 (0.53) | LMNAHTTNPC1EPHX2GAA | |
| SCHEMBL30447349 | 0.87 | PTGER3 (0.53) | LMNAHTTNPC1EPHX2GAA | |
| SCHEMBL12970788 | 0.87 | ALDH1A1 (0.62) | LMNAHTTNPC1EPHX2GAA | |
| SCHEMBL6114177 | 0.87 | GAA (0.62) | LMNAHTTNPC1EPHX2GAA | |
| SCHEMBL16480608 | 0.87 | EPHX2 (0.52) | LMNAHTTNPC1EPHX2GAA | |
| SCHEMBL17653849 | 0.87 | EPHX2 (0.52) | LMNAHTTNPC1EPHX2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 280 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119912454-A | Antitumor compound and preparation method and application thereof | 承德医学院 | 2025-05-02 | — | — | CN | claimed |
| WO-2024213932-A1 | DRIVING AXON REGENERATION BY NOVEL ENPP1 INHIBITORS | THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2024-10-17 | — | — | WO | claimed |
| CN-113444020-B | Synthesis method of alpha-isopropyl-3,4-dimethoxyphenylacetonitrile | 常州大学 | 2023-03-21 | — | — | CN | claimed |
| CN-113444020-A | Synthesis method of alpha-isopropyl-3, 4-dimethoxyphenylacetonitrile | 常州大学 | 2021-09-28 | — | — | CN | claimed |
| EP-1773768-B1 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2018-08-22 | — | — | EP | claimed |
| EP-2627631-B1 | PYRROLIDINONES AS METAP2 INHIBITORS | MERCK PATENT GMBH (DE) | 2015-12-16 | — | — | EP | claimed |
| EP-2205573-B1 | TETRAZOLE-SUBSTITUTED ARYL AMIDE DERIVATIVES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2013-10-23 | — | — | EP | claimed |
| EP-2074089-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2013-09-18 | — | — | EP | claimed |
| EP-1971600-B1 | ISOXAZOLE DERIVATIVES AND USE THEREOF | SK BIOPHARMACEUTICALS CO LTD (KR) | 2013-08-21 | — | — | EP | claimed |
| EP-2340021-B1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | HOFFMANN LA ROCHE (CH) | 2012-11-07 | — | — | EP | claimed |
| WO-2004089416-A2 | COMBINATION OF AN 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND AN ANTIHYPERTENSIVE AGENT | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | claimed |
| WO-2004089470-A2 | NEW AMIDE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | claimed |
| WO-2004089415-A2 | COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | claimed |
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | claimed |
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | claimed |
| WO-2004018461-A2 | ANTIBACTERIAL BENZOIC ACID DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | claimed |
| WO-2004018428-A1 | ANTIBACTERIAL BENZOIC ACID DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | claimed |
| EP-1370562-A1 | THIENO[2,3-D]PYRIMIDINDIONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2003-12-17 | — | — | EP | claimed |
| WO-2002064598-A1 | THIENO'2,3-D PYRIMIDINDIONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | claimed |
| EP-0030009-B1 | NEW DERIVATIVES OF THE 9-CIS-6,6'-DIAPO-PSI,PSI-CAROTENEDIOIC ACID, PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Simes S.p.A. (IT) | 1983-05-11 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | GABRD, PHB1, GABBR1 | LMNA 4062/4885HTT 2287/4885NPC1 3891/4885 |
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | GABRD, GABBR1, GABRA1 | LMNA 3376/4885HTT 1599/4885NPC1 3778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.